Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to $394921.0.

  • Abeona Therapeutics' Gains from Investment Securities fell 9739.43% to $394921.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $394921.0, marking a year-over-year decrease of 9895.49%. This contributed to the annual value of $584700.0 for FY2024, which is 22664.62% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Gains from Investment Securities of $394921.0 as of Q3 2025, which was down 9739.43% from $5.4 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Gains from Investment Securities high stood at $17.3 million for Q1 2024, and its period low was -$6.8 million during Q4 2024.
  • Over the past 5 years, Abeona Therapeutics' median Gains from Investment Securities value was $178859.0 (recorded in 2024), while the average stood at $1.7 million.
  • The largest annual percentage gain for Abeona Therapeutics' Gains from Investment Securities in the last 5 years was 616500.0% (2022), contrasted with its biggest fall of 30510000.0% (2022).
  • Quarter analysis of 5 years shows Abeona Therapeutics' Gains from Investment Securities stood at -$16000.0 in 2021, then plummeted by 33575.0% to -$5.4 million in 2022, then soared by 178.51% to $4.2 million in 2023, then tumbled by 260.17% to -$6.8 million in 2024, then soared by 105.83% to $394921.0 in 2025.
  • Its Gains from Investment Securities stands at $394921.0 for Q3 2025, versus $5.4 million for Q2 2025 and $531700.0 for Q1 2025.